The CDC has denied a request to validate a high-volume measles test, citing “other competing priorities,” a decision that could hamper outbreak response efforts. The request came from the West Coast Health Alliance, representing California, Hawaii, Oregon, and Washington.
In May, these states asked the CDC to validate a new method for rapid, high-volume measles testing. After a two-month wait, the agency declined, according to a letter from the alliance to CDC Director Erica Schwartz.
Why States Sought a High-Volume Measles Test
The West Coast Health Alliance pushed for the test to prepare for major outbreaks. They argued that a high-throughput assay would “dramatically strengthen” laboratories’ ability to respond quickly.
Such a test would also help preparedness for other high-priority pathogens like Ebola or hantavirus, as well as emerging threats. Currently, labs rely on lower-volume tests, which can slow response times during surges.
CDC’s Response and Priorities
The CDC declined the request, stating it is “ensuring state and local health departments have the support needed to strengthen measles detection and outbreak response,” according to Emily Hilliard, a spokesperson for the US Department of Health and Human Services (HHS).
Hilliard said the agency was “prioritizing emerging technologies” to respond to the measles outbreak. However, she did not answer whether the CDC plans to validate a high-throughput measles assay in the future.
What This Means for Outbreak Preparedness
The denial raises concerns about the nation’s ability to quickly scale up testing during outbreaks. High-volume testing is critical for early detection and containment, especially for highly contagious diseases like measles.
Without CDC validation, states may face hurdles in implementing rapid, large-scale testing. This could delay identification of cases and hinder efforts to prevent spread.
- CDC denied a request to validate a high-volume measles test, citing competing priorities.
- The request came from California, Hawaii, Oregon, and Washington through the West Coast Health Alliance.
- A high-throughput test would significantly enhance lab response capabilities during outbreaks.
- The CDC says it is prioritizing emerging technologies but did not confirm plans for assay validation.
- The decision may impact preparedness for measles and other infectious diseases.
Comparing Testing Approaches
| Test Type | Volume Capacity | Validation Status | Use Case |
|---|---|---|---|
| Current lower-volume tests | Low to moderate | Validated | Routine testing, small outbreaks |
| Proposed high-volume test | High | Not CDC-validated | Large outbreaks, surge capacity |
The table illustrates the trade-offs. While current tests are validated and reliable for typical scenarios, they may not suffice during a major outbreak. The proposed high-volume test could fill that gap but lacks CDC validation.
The Broader Implications for Public Health
This decision comes amid a measles outbreak in Pennsylvania, where CDC disease detectives have been deployed. The state has also sought emergency aid from the CDC. The background to this story is set out in Pennsylvania Seeks CDC Emergency Aid for Measles Outbreak. A related thread runs through CDC Disease Detective Deployed to Pennsylvania Measles Outbreak. Earlier coverage in CDC Cyclosporiasis Outbreak Expands to 15 States shows how the argument developed.
Effective testing is a cornerstone of outbreak response. Delays in validation could leave states less prepared for future surges, not just for measles but for other pathogens. A closer look at the same subject appears in CDC Cyclosporiasis Outbreak Expands to 15 States, Including. Anyone following the wider picture can start with Cyclosporiasis Outbreak Expands to 9 States: CDC Investigates. The same theme surfaces in Best Cost-Effective AI Video Interview Solutions For High-Volume Recruitment, which takes a different angle.
As the situation evolves, stakeholders will watch whether the CDC reconsiders its stance or provides alternative support to states. The balance between competing priorities and outbreak readiness remains a critical challenge. Context on how this played out before sits in CDC Declares Largest Cyclospora Outbreak Officially. A companion piece, Cyclosporiasis Outbreak Expands: CDC Investigates 7,400 Cases, approaches the same subject from another angle.
FAQ
What did the CDC deny?
The CDC denied a request to validate a high-volume measles test that would allow labs to process more samples quickly during outbreaks.
Which states requested the test?
California, Hawaii, Oregon, and Washington, through the West Coast Health Alliance, asked the CDC to validate the test.
Why did the CDC deny the request?
The CDC cited “other competing priorities” and said it is focusing on emerging technologies and supporting state and local health departments.
How does this affect outbreak response?
Without a validated high-volume test, states may struggle to rapidly test and contain outbreaks, potentially delaying public health interventions.